Cell and Molecular Biology of Epidermal Growth Factor Receptor

International Review of Cell and Molecular Biology

Volumn 313, Issue , 2014, Pages 145-178

  Ceresa, Brian P ^a   Peterson, Joanne L ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Cancer; Endocytic trafficking; Epidermal growth factor receptor; Epithelial cells; ErbB family; Receptor tyrosine kinase

Indexed keywords

CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HETERODIMER; LIGAND; PHOSPHOTRANSFERASE; PHOSPHOTYROSINE; RECEPTOR;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; CONFORMATIONAL TRANSITION; CYTOLOGY; DEVELOPMENTAL BIOLOGY; DIMERIZATION; EPITHELIUM CELL; HOMEOSTASIS; HUMAN; INTRACELLULAR SIGNALING; LIGAND BINDING; MOLECULAR BIOLOGY; NEOPLASM; NONHUMAN; OLIGOMERIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SURFACE PROPERTY; TISSUE DISTRIBUTION; UBIQUITINATION; ANIMAL; BINDING SITE; CHEMISTRY; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; HUMANS; LIGANDS; MUTATION; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; UBIQUITINATION;

EID: 84908880944     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800177-6.00005-0     Document Type: Chapter

References (180)

1. Adak S., Yang K.S., Macdonald-Obermann J., Pike L.J. The membrane-proximal intracellular domain of the epidermal growth factor receptor underlies negative cooperativity in ligand binding. J. Biol. Chem. 2011, 286:45146-45155.
2. Alvarado D., Klein D.E., Lemmon M.A. Structural basis for negative cooperativity in growth factor binding to an EGF receptor. Cell 2010, 142:568-579.
3. Alwan H.A., van Zoelen E.J., van Leeuwen J.E. Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J. Biol. Chem. 2003, 278:35781-35790.
4. Arteaga C.L., Engelman J.A. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014, 25:282-303.
5. Bache K.G., Slagsvold T., Cabezas A., Rosendal K.R., Raiborg C., Stenmark H. The growth-regulatory protein HCRP1/hVps37A is a subunit of mammalian ESCRT-1 and mediates receptor down-regulation. Mol. Biol. Cell 2006, 15:4337-4346.
6. Bache K.G., Stuffeers S., Malerod L., Slagsvold T., Raiborg C., Lechardeur D., Walchli S., Luckacs G.L., Brech A., Stenmark H. The ESCRT-III subunit hVps24 is required for degradation but not silencing of the epidermal growth factor receptor. Mol. Biol. Cell 2006, 17:2513-2523.
7. Bajaj M., Waterfield M.D., Schlessinger J., Taylor W.R., Blundell T. On the tertiary structure of the extracellular domains of the epidermal growth factor and insulin receptors. Biochim. Biophys. Acta 1987, 916:220-226.
8. Batra S.K., Castelino-Prabhu S., Wikstrand C.J., Zhu X., Humphrey P.A., Friedman H.S., Bigner D.D. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. Mol. Biol. J. Am. Assoc. Cancer Res. 1995, 6:1251-1259.
9. Baulida J., Kraus M.H., Alimandi M., DiFiore P.P., Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 1996, 271:5251-5257.
10. Bellevicine C., Malapelle U., de Luca C., Iaccarino A., Troncone G. EGFR analysis: current evidence and future directions. Diagn. Cytopathol 2014, http://dx.doi.org/10.1002/dc.23142.
11. Bennett C., Paterson I.M., Corbishley C.M., Luqmani Y.A. Expression of growth factor and epidermal growth factor receptor encoded transcripts in human gastric tissues. Cancer Res. 1989, 49:2104-2111.
12. Blasband A.J., Rogers K.T., Chen X.R., Azizkhan J.C., Lee D.C. Characterization of the rat transforming growth factor alpha gene and identification of promoter sequences. Mol. Cell Biol. 1990, 10:2111-2121.
13. Blum M. A null mutation in TGF-alpha leads to a reduction in midbrain dopaminergic neurons in the substantia nigra. Nat. Neurosci. 1998, 1:374-377.
14. Boeri Erba E., Matthiesen R., Bunkenborg J., Schulze W.X., Di Stefano P., Cabodi S., Tarone G., Defilippi P., Jensen O.N. Quantitation of multisite EGF receptor phosphorylation using mass spectrometry and a novel normalization approach. J. Proteome Res. 2007, 6:2768-2785.
15. Bouyain S., Longo P.A., Li S., Ferguson K.M., Leahy D.J. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15024-15029.
16. Breitbart H., Etkovitz N. Role and regulation of EGFR in actin remodeling in sperm capacitation and the acrosome reaction. Asian J. Androl. 2011, 13:106-110.
17. Cappuzzo F., Bartolini S., Ceresoli G.L., Tamberi S., Spreafico A., Lombardo L., Gregorc V., Toschi L., Calandri C., Villa E., Crino L. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br. J. Cancer 2004, 90:82-86.
18. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., Witta S., Danenberg K., Domenichini I., Ludovini V., Magrini E., Gregorc V., Doglioni C., Sidoni A., Tonato M., Franklin W.A., Crino L., Bunn P.A., Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 2005, 97:643-655.
19. Carpenter G., Lembach K.J., Morrison M.M., Cohen S. Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. J. Biol. Chem. 1975, 250:4297-4304.
20. Carrasco-Garcia E., Saceda M., Martinez-Lacaci I. Role of receptor tyrosine kinases and their ligands in glioblastoma. Cells 2014, 3:199-235.
21. Chen B., Bronson R.T., Klaman L.D., Hampton T.G., Wang J.F., Green P.J., Magnuson T., Douglas P.S., Morgan J.P., Neel B.G. Mice mutant for EGFR and Shp2 have defective cardiac semilunar valvulogenesis. Nat. Genet. 2000, 24:296-299.
22. Chen J.K., Falck J.R., Reddy K.M., Capdevila J., Harris R.C. Epoxyeicosatrienoic acids and their sulfonimide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells. J. Biol. Chem. 1998, 273:29254-29261.
23. Chen T.C., Liu Y.W., Huang Y.H., Yeh Y.C., Chou T.Y., Wu Y.C., Wu C.C., Chen Y.R., Cheng H.C., Lu P.J., Lai J.M., Huang C.Y. Protein phosphorylation profiling using an in situ proximity ligation assay: phosphorylation of AURKA-elicited EGFR-Thr654 and EGFR-Ser1046 in lung cancer cells. PLoS One 2013, 8:e55657.
24. Cho H.S., Leahy D.J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002, 297:1330-1333.
25. Chong C.R., Janne P.A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 2013, 19:1389-1400.
26. Clayton A.H., Orchard S.G., Nice E.C., Posner R.G., Burgess A.W. Predominance of activated EGFR higher-order oligomers on the cell surface. Growth Factors 2008, 26:316-324.
27. Clayton A.H., Tavarnesi M.L., Johns T.G. Unligated epidermal growth factor receptor forms higher order oligomers within microclusters on A431 cells that are sensitive to tyrosine kinase inhibitor binding. Biochemistry 2007, 46:4589-4597.
28. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the newborn animal. J. Biol. Chem. 1962, 237:1555-1562.
29. Crombet T., Torres L., Neninger E., Catala M., Solano M.E., Perera A., Torres O., Iznaga N., Torres F., Perez R., Lage A. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J. Immunother. 2003, 26:139-148.
30. Dacic S., Flanagan M., Cieply K., Ramalingam S., Luketich J., Belani C., Yousem S.A. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am. J. Clin. Pathol. 2006, 125:860-865.
31. Dahlhoff M., Schafer M., Wolf E., Schneider M.R. Genetic deletion of the EGFR ligand epigen does not affect mouse embryonic development and tissue homeostasis. Exp. Cell Res. 2013, 319:529-535.
32. de Melker A.A., van der Horst G., Borst J. Ubiquitin ligase activity of c-Cbl guides the epidermal growth factor receptor into clathrin-coated pits by two distinct modes of Eps15 recruitment. J. Biol. Chem. 2004, 279:55465-55473.
33. de Melker A.A., van der Horst G., Calafat J., Jansen H., Borst J. c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route. J. Cell Sci. 2001, 114:2167-2178.
34. Decker S.J. Transmembrane signaling by epidermal growth factor receptors lacking autophosphorylation sites. J. Biol. Chem. 1993, 268:9176-9179.
35. Defize L.H.K., Boonstra J., Meisenhelder J., Kruijer W., Tertoolen L.G.J., Tilly B.C., Hunter T., van Bergen en Henegouwen P.M.P., Moolenaar W.H., de Laat S.W. Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J. Cell Biol. 1989, 109:2495-2507.
36. Duan L., Miura Y., Dimri M., Majumder B., Dodge I.L., Reddi A.L., Ghosh A., Fernandes N., Zhou P., Mullane-Robinson K., Rao N., Donoghue S., Rogers R.A., Bowtell D., Naramura M., Gu H., Band V., Band H. Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J. Biol. Chem. 2003, 278:28950-28960.
37. Dulin N.O., Sorokin A., Douglas J.G. Arachidonate-induced tyrosine phosphorylation of epidermal growth factor receptor and Shc-Grb2-Sos association. Hypertension 1998, 32:1089-1093.
38. Eden E.R., Huang F., Sorkin A., Futter C.E. The role of EGF receptor ubiquitination in regulating its intracellular traffic. Traffic 2012, 13:329-337.
39. Ferguson K.M., Berger M.B., Medrola J.M., Cho H.S., Leahy D.J., Lemmon M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 2003, 11:507-517.
40. Fry W.H., Kotelawala L., Sweeney C., Carraway K.L. Mechanisms of ErbB receptor negative regulation and relevance in cancer. Exp. Cell Res. 2009, 315:697-706.
41. Furuuchi K., Berezov A., Kumagai T., Greene M.I. Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors. J. Immunol. 2007, 178:1021-1029.
42. Galcheva-Gargova Z., Theroux S.J., Davis R.J. The epidermal growth factor receptor is covalently linked to ubiquitin. Oncogene 1995, 11:2649-2655.
43. Gan H.K., Cvrljevic A.N., Johns T.G. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 2013, 280:5350-5370.
44. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Kofler M., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 2003, 11:495-505.
45. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005, 23:3235-3242.
46. Glasgow W.C., Hui R., Everhart A.L., Jayawickreme S.P., Angerman-Stewart J., Han B.B., Eling T.E. The linoleic acid metabolite, (13S)-hydroperoxyoctadecadienoic acid, augments the epidermal growth factor receptor signaling pathway by attenuation of receptor dephosphorylation. Differential response in Syrian hamster embryo tumor suppressor phenotypes. J. Biol. Chem. 1997, 272:19269-19276.
47. Goh L.K., Huang F., Kim W., Gygi S., Sorkin A. Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor. J. Cell Biol. 2010, 189:871-883.
48. Goldman B., Mach A., Wurzel J. Epidermal growth factor promotes a cardiomyoblastic phenotype in human fetal cardiac myocytes. Exp. Cell Res. 1996, 228:237-245.
49. Grovdal L.M., Stang E., Sorkin A., Madshus I.H. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp. Cell Res. 2004, 300:388-395.
50. Gruenberg J., Maxfield F.R. Membrane transport in the endocytic pathway. Curr. Opin. Cell Biol. 1995, 7:552-563.
51. Guo L., Kozlosky C.J., Ericsson L.H., Daniel T.O., Cerretti D.P., Johnson R.S. Studies of ligand-induced site-specific phosphorylation of epidermal growth factor receptor. J. Am. Soc. Mass Spectrom. 2003, 14:1022-1031.
52. Haglund K., Dikic I. The role of ubiquitylation in receptor endocytosis and endosomal sorting. J. Cell Sci. 2012, 125:265-275.
53. Haglund K., Sigismund S., Polo S., Szymkiewicz I., Di Fiore P.P., Dikic I. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat. Cell Biol. 2003, 5:461-466.
54. Hansen L.A., Alexander N., Hogan M.E., Sundberg J.P., Dlugosz A., Threadgill D.W., Magnuson T., Yuspa S.H. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am. J. Pathol. 1997, 150:1959-1975.
55. Harvey T.S., Wilkinson A.J., Tappin M.J., Cooke R.M., Campbell I.D. The solution structure of human transforming growth factor alpha. Eur. J. Biochem 1991, 198:555-562.
56. Hendriks B.S., Opresko L.K., Wiley H.S., Lauffenburger D. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. J. Biol. Chem. 2003, 278:23343-23351.
57. Herbst J.J., Opresko L.K., Walsh B.J., Lauffenburger D.A., Wiley H.S. Regulation of Postendocytic trafficking of the epidermal growth factor receptor through endosomal retention. J. Biol. Chem. 1994, 269:12865-12873.
58. Higashiyama S., Lau K., Besner G.E., Abraham J.A., Klagsbrun M. Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J. Biol. Chem. 1992, 267:6205-6212.
59. Honegger A.M., Kris R.M., Ullrich A., Schlessinger J. Evidence that autophosphorylation of solubilized receptors for epidermal growth factor is mediated by intermolecular cross-phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:925-929.
60. Huang F., Goh L.K., Sorkin A. EGF receptor ubiquitination is not necessary for its internalization. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16904-16909.
61. Huang F., Kirkpatrick D., Jiang X., Gygi S., Sorkin A. Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol. Cell 2006, 21:737-748.
62. Huang F., Zeng X., Kim W., Balasubramani M., Fortian A., Gygi S.P., Yates N.A., Sorkin A. Lysine 63-linked polyubiquitination is required for EGF receptor degradation. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:15722-15727.
63. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 2009, 21:177-184.
64. Jackson L.F., Qiu T.H., Sunnarborg S.W., Chang A., Zhang C., Patterson C., Lee D.C. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J. 2003, 22:2704-2716.
65. Jacobs B., De Roock W., Piessevaux H., Van Oirbeek R., Biesmans B., De Schutter J., Fieuws S., Vandesompele J., Peeters M., Van Laethem J.L., Humblet Y., Penault-Llorca F., De Hertogh G., Laurent-Puig P., Van Cutsem E., Tejpar S. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2009, 27:5068-5074.
66. Jiang X., Huang F., Marusyk A., Sorkin A. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol. Biol. Cell 2003, 14:858-870.
67. Joazeiro C.A.P., Wing S.S., Huang H.-K., Leverson J.D., Hunter T., Liu Y.-C. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999, 286:309-312.
68. Johanessen L.E., Ringerike T., Molnes J., Madshus I.H. Epidermal growth factor receptor efficiently activates mitogen-activated protein kinase in HeLa cells and HepG2 cells conditionally defective in clathrin-dependent endocytosis. Exp. Cell Res. 2000, 260:136-145.
69. Johns T.G., Mellman I., Cartwright G.A., Ritter G., Old L.J., Burgess A.W., Scott A.M. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. FASEB J.: Official Publ. Fed. Am. Soc. Exp. Biol. 2005, 19:780-782.
70. Jorissen R.N., Walker F., Pouliot N., Garrett T.P.J., Ward C.W., Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 2003, 284:31-53.
71. Kawamoto T., Sato J.D., Le A., Polikoff J., Sato G.H., Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl. Acad. Sci. United States Am. 1983, 80:1337-1341.
72. Kehasse A., Rich C.B., Lee A., McComb M.E., Costello C.E., Trinkaus-Randall V. Epithelial wounds induce differential phosphorylation changes in response to purinergic and EGF receptor activation. Am. J. Pathol. 2013, 183:1841-1852.
73. Kim J., Eckhart A.D., Eguchi S., Koch W.J. Beta-adrenergic receptor-mediated DNA synthesis in cardiac fibroblasts is dependent on transactivation of the epidermal growth factor receptor and subsequent activation of extracellular signal-regulated kinases. J. Biol. Chem. 2002, 277:32116-32123.
74. Kim Y.T., Park S.W., Kim J.W. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gyn. Oncol. 2002, 87:84-89.
75. Koland J.G. Coarse-grained molecular simulation of epidermal growth factor receptor protein tyrosine kinase multi-site self-phosphorylation. PLoS Comput. Biol. 2014, 10:e1003435.
76. Kopp R., Rothbauer E., Ruge M., Arnholdt H., Spranger J., Muders M., Pfeiffer D.G., Schildberg F.W., Pfeiffer A. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res. 2003, 162:115-132.
77. Koshibu K., Levitt P. Sex differences in expression of transforming growth factor-alpha and epidermal growth factor receptor mRNA in Waved-1 and C57Bl6 mice. Neuroscience 2005, 134:877-887.
78. Krall J.A., Beyer E.M., MacBeath G. High- and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways. PLoS One 2011, 6:e15945.
79. Lax I., Burgess W.H., Bellot F., Ullrich A., Schlessinger J., Givol D. Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol. Cell. Biol. 1988, 8:1831-1834.
80. Lee D., Pearsall R.S., Das S., Dey S.K., Godfrey V.L., Threadgill D.W. Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage. Mol. Cell Biol. 2004, 24:8907-8916.
81. Lenferink A.E.G., Pinkas-Kramarski R., van de Poll M.L.M., van Vugt M.J.H., Klapper L.N., Tzahar E., Waterman H., Sela M., van Zoelan E.J.J., Yarden Y. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 1998, 17:3385-3397.
82. Levkowitz G., Klapper L.N., Tzahar E., Freywald A., Sela M., Yarden Y. Coupling of the c-Cbl protooncogene product to Erb-1/EGF-receptor but not to other ErbB proteins. Oncogene 1996, 12:1117-1125.
83. Levkowitz G., Waterman H., Zamir E., Kam Z., Oved S., Langdon W.Y., Beguinot L., Geiger B., Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998, 12:3663-3674.
84. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
85. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., Bourguignon L., Hung M.C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 2001, 3:802-808.
86. Linggi B., Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 2006, 16:649-656.
87. Longva K.E., Blystad F.D., Stang E., Larsen A.M., Johannessen L.E., Madshus I.H. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J. Cell. Biol. 2002, 156:843-854.
88. Louie G.V., Yang W., Bowman M.E., Choe S. Crystal structure of the complex of diphtheria toxin with an extracellular fragment of its receptor. Mol. Cell 1997, 1:67-78.
89. Luetteke N.C., Phillips H.K., Qiu T.H., Copeland N.G., Earp H.S., Jenkins N.A., Lee D.C. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev. 1994, 8:399-413.
90. Luetteke N.C., Qiu T.H., Fenton S.E., Troyer K.L., Riedel R.F., Chang A., Lee D.C. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1999, 126:2739-2750.
91. Luetteke N.C., Qiu T.H., Peiffer R.L., Oliver P., Smithies O., Lee D.C. TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 1993, 73:263-278.
92. Macdonald J.L., Pike L.J. Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:112-117.
93. Macdonald-Obermann J.L., Adak S., Landgraf R., Piwnica-Worms D., Pike L.J. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. J. Biol. Chem. 2013, 288:30773-30784.
94. Magun B.E., Matrisian L.M., Bowden G.T. Epidermal growth factor. Ability of tumor promoter to alter its degradation, receptor affinity and receptor number. J. Biol. Chem. 1980, 255:6373-6381.
95. Mann G.B., Fowler K.J., Gabriel A., Nice E.C., Williams R.L., Dunn A.R. Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 1993, 73:249-261.
96. Martin-Fernandez M., Clarke D.T., Tobin M.J., Jones S.V., Jones G.R. Preformed oligomeric epidermal growth factor receptors undergo an ectodomain structure change during signaling. Biophys. J. 2002, 82:2415-2427.
97. Massague J. Transforming growth factor-alpha. A model for membrane-anchored growth factors. J. Biol. Chem. 1990, 265:21393-21396.
98. Mayes E.L., Waterfield M.D. Biosynthesis of the epidermal growth factor receptor in A431 cells. EMBO J. 1984, 3:531-537.
99. Mellman I., Yarden Y. Endocytosis and cancer. Cold Spring Harb. Perspect. Biol. 2013, 5:a016949.
100. Mendrola J.M., Shi F., Park J.H., Lemmon M.A. Receptor tyrosine kinases with intracellular pseudokinase domains. Biochem. Soc. Trans. 2013, 41:1029-1036.
101. Miura K., Doura H., Aizawa T., Tada H., Seno M., Yamada H., Kawano K. Solution structure of betacellulin, a new member of EGF-family ligands. Biochem. Biophys. Res. Commun. 2002, 294:1040-1046.
102. Modjtahedi H., Hickish T., Nicolson M., Moore J., Styles J., Eccles S., Jackson E., Salter J., Sloane J., Spencer L., Priest K., Smith I., Dean C., Gore M. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br. J. Cancer 1996, 73:228-235.
103. Moriai T., Kobrin M.S., Hope C., Speck L., Korc M. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:10217-10221.
104. Mosesson Y., Mills G.B., Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat. Rev. Cancer 2008, 8:835-850.
105. Mosesson Y., Shtiegman K., Katz M., Zwang Y., Vereb G., Szollosi J., Yarden Y. Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J. Biol. Chem. 2003, 278:21323-21326.
106. Ni C.Y., Murphy M.P., Golde T.E., Carpenter G. gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001, 294:2179-2181.
107. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 2001, 37(Suppl. 4):S9-S15.
108. Nishikawa R., Ji X.D., Harmon R.C., Lazar C.S., Gill G.N., Cavenee W.K., Huang H.J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:7727-7731.
109. Offterdinger M., Schofer C., Weipoltshammer K., Grunt T.W. c-erbB-3: a nuclear protein in mammary epithelial cells. J. Cell. Biol. 2002, 157:929-939.
110. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110:775-787.
111. Orellana S.A., Sweeney W.E., Neff C.D., Avner E.D. Epidermal growth factor receptor expression is abnormal in murine polycystic kidney. Kidney Int. 1995, 47:490-499.
112. Peterson J.L., Phelps E.D., Doll M.A., Schaal S., Ceresa B.P. Analysis of EGFR ligands found in human tears reveals differences in corneal epithelial wound healing and ligand induced EGFR signaling. Inv Opth Vis Sci. 2014, 55:2870-2880.
113. Pines G., Kostler W.J., Yarden Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett. 2010, 584:2699-2706.
114. Puddicombe S.M., Polosa R., Richter A., Krishna M.T., Howarth P.H., Holgate S.T., Davies D.E. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2000, 14:1362-1374.
115. Qian X., LeVea C.M., Freeman J.K., Dougall W.C., Greene M.I. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:1500-1504.
116. Ravid T., Heidinger J.M., Gee P., Khan E.M., Goldkorn T. c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes. J. Biol. Chem. 2004, 279:37153-37162.
117. Razi M., Futter C.E. Distinct roles for Tsg101 and Hrs in multivesicular body formation and inward vesiculation. Mol. Biol. Cell 2006, 17:3469-3483.
118. Reiter J.L., Threadgill D.W., Eley G.D., Strunk K.E., Danielsen A.J., Sinclair C.S., Pearsall R.S., Green P.J., Yee D., Lampland A.L., Balasubramaniam S., Crossley T.D., Magnuson T.R., James C.D., Maihle N.J. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics 2001, 71:1-20.
119. Repetto E., Yoon I.S., Zheng H., Kang D.E. Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. J. Biol. Chem. 2007, 282:31504-31516.
120. Ribeiro F.A., Noguti J., Oshima C.T., Ribeiro D.A. Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach. Anticancer Res. 2014, 34:1547-1552.
121. Richards W.G., Sweeney W.E., Yoder B.K., Wilkinson J.E., Woychik R.P., Avner E.D. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J. Clin. Invest. 1998, 101:935-939.
122. Riethmacher D., Sonnenberg-Riethmacher E., Brinkmann V., Yamaai T., Lewin G.R., Birchmeier C. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature 1997, 389:725-730.
123. Roepstorff K., Grandal M.V., Henriksen L., Knudsen S.L., Lerdrup M., Grovdal L., Willumsen B.M., van Deurs B. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 2009, 10:1115-1127.
124. Rowinsky E.K. The erbB family: targets for therapeutic Development against Cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Ann. Rev. Med. 2004, 55:433-457.
125. Rush J.S., Quinalty L.M., Engelman L., Sherry D.M., Ceresa B.P. Endosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosis. J. Biol. Chem. 2012, 287:712-722.
126. Rutten M.J., Dempsey P.J., Luttropp C.A., Hawkey M.A., Sheppard B.C., Crass R.A., Deveney C.W., Coffey R.J. Identification of an EGF/TGF-alpha receptor in primary cultures of guinea pig gastric mucous epithelial cells. Am. J. Physiol. 1996, 270:G604-G612.
127. Santoro F., Cozzani E., Parodi A. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor. J. Dermatol. Treat. 2006, 17:160-161.
128. Sargent E.R., Gomella L.G., Belldegrun A., Linehan W.M., Kasid A. Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J. Urol. 1989, 142:1364-1368.
129. Sato K., Nakamura T., Mizuguchi M., Miura K., Tada M., Aizawa T., Gomi T., Miyamoto K., Kawano K. Solution structure of epiregulin and the effect of its C-terminal domain for receptor binding affinity. FEBS Lett. 2003, 553:232-238.
130. Scheving L.A., Stevenson M.C., Taylormoore J.M., Traxler P., Russell W.E. Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation. Biochem. Biophys. Res. Commun. 2002, 290:197-203.
131. Schlessinger J. Allosteric regulation of the epidermal growth factor receptor kinase. J. Cell. Biol. 1986, 103:2067-2072.
132. Schulze W.X., Deng L., Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 2005, 1:0008.
133. Seno M., Tada H., Kosaka M., Sasada R., Igarashi K., Shing Y., Folkman J., Ueda M., Yamada H. Human betacellulin, a member of the EGF family dominantly expressed in pancreas and small intestine, is fully active in a monomeric form. Growth Factors 1996, 13:181-191.
134. Shirasawa S., Sugiyama S., Baba I., Inokuchi J., Sekine S., Ogino K., Kawamura Y., Dohi T., Fujimoto M., Sasazuki T. Dermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:13921-13926.
135. Shoelson S.E. SH2 and PTB domain interactions in tyrosine kinase signal transduction. Curr. Opin. Chem. Biol. 1997, 1:227-234.
136. Shoyab M., De Larco J.E., Todaro G.J. Biologically active phorbol esters specifically alter affinity of epidermal growth factor membrane receptors. Nature 1979, 279:387-391.
137. Shoyab M., McDonald V.L., Bradley J.G., Todaro G.J. Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:6528-6532.
138. Sibilia M., Steinbach J.P., Stingl L., Aguzzi A., Wagner E.F. A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J. 1998, 17:719-731.
139. Sibilia M., Wagner E.F. Strain-dependent epithelial defects in mice lacking the EGFR. Science 1995, 269:234-238.
140. Sigismund S., Argenzio E., Tosoni D., Cavallaro E., Polo S., Di Fiore P.P. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev. Cell 2008, 15:209-219.
141. Sigismund S., Woelk T., Puri C., Maspero E., Tacchetti C., Transidico P., DiFiore P.P., Polo S. Clathrin-independent endocytosis of ubiquinated cargos. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2760-2765.
142. Singh A.B., Sugimoto K., Harris R.C. Juxtacrine activation of epidermal growth factor (EGF) receptor by membrane-anchored heparin-binding EGF-like growth factor protects cells from anoikis while maintaining an epithelial phenotype. J. Biol. Chem. 2007, 282:32890-32901.
143. Sirisaengtaksin N., Gireud M., Yan Q., Kubota Y., Meza D., Waymire J.C., Zage P.E., Bean A.J. UBE4B protein couples ubiquitination and sorting machineries to enable epidermal growth factor receptor (EGFR) degradation. J. Biol. Chem. 2014, 289:3026-3039.
144. Sorkin A., Goh L.K. Endocytosis and intracellular trafficking of ErbBs. Exp. Cell Res. 2009, 315:683-696.
145. Sorkin A., von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat. Rev. Mol. Cell. Biol. 2009, 10:609-622.
146. Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277:46265-46272.
147. Stang E., Blystad F.D., Kazazic M., Bertelsen V., Brodahl T., Raiborg C., Stenmark H., Madshus I.H. Cbl-dependent Ubiquitination is required for progression of EGF receptors into clathrin-coated pits. Mol. Biol. Cell 2006, 15:3591-3604.
148. Strachan L., Murison J.G., Prestidge R.L., Sleeman M.A., Watson J.D., Kumble K.D. Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J. Biol. Chem. 2001, 276:18265-18271.
149. Sundberg J.P. Handbook of Mouse Mutations with Skin and Hair Abnormalities 1994, CRC Press, Boca Raton, FL.
150. Takemura T., Yoshida Y., Kiso S., Kizu T., Furuta K., Ezaki H., Hamano M., Egawa M., Chatani N., Kamada Y., Imai Y., Higashiyama S., Iwamoto R., Mekada E., Takehara T. Conditional loss of heparin-binding EGF-like growth factor results in enhanced liver fibrosis after bile duct ligation in mice. Biochem. Biophys. Res. Commun. 2013, 437:185-191.
151. Takemura T., Yoshida Y., Kiso S., Saji Y., Ezaki H., Hamano M., Kizu T., Egawa M., Chatani N., Furuta K., Kamada Y., Iwamoto R., Mekada E., Higashiyama S., Hayashi N., Takehara T. Conditional knockout of heparin-binding epidermal growth factor-like growth factor in the liver accelerates carbon tetrachloride-induced liver injury in mice. Hepatol. Res. 2013, 43:384-393.
152. Tao R.H., Maruyama I.N. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J. Cell Sci. 2008, 121:3207-3217.
153. Tovey S.M., Dunne B., Witton C.J., Cooke T.G., Bartlett J.M. HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4. Breast Cancer Res. BCR 2006, 8:R19.
154. Toyoda H., Komurasaki T., Uchida D., Morimoto S. Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem. J. 1997, 326(Pt 1):69-75.
155. Toyoda H., Komurasaki T., Uchida D., Takayama Y., Isobe T., Okuyama T., Hanada K. Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J. Biol. Chem. 1995, 270:7495-7500.
156. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., Lorimer I., Zhang T., Liu N., Daneshmand M., Marrano P., da Cunha Santos G., Lagarde A., Richardson F., Seymour L., Whitehead M., Ding K., Pater J., Shepherd F.A. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl. J. Med. 2005, 353:133-144.
157. Tullo A.B., Esmaeli B., Murray P.I., Bristow E., Forsythe B.J., Faulkner K. Ocular findings in patients with solid tumour treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ("Iressa", ZD1839) in phase I and II clinical trials. Eye 2005, 19:729-738.
158. Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., Lee J., Yarden Y., Libermann T.A., Schlessinger J., et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984, 309:418-425.
159. Ushiro H., Cohen S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J. Biol. Chem. 1980, 255:8363-8365.
160. Vargas G.A., Fantino E., George-Nascimento C., Gargus J.J., Haigler H.T. Reduced epidermal growth factor receptor expression in hypohidrotic ectodermal dysplasia and tabby mice. J. Clin. Invest. 1996, 97:2426-2432.
161. Vassar R., Fuchs E. Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation. Genes Dev. 1991, 5:714-727.
162. Vaughan T.J., Pascall J.C., Brown K.D. Nucleotide sequence and tissue distribution of mouse transforming growth factor-alpha. Biochim. Biophys. Acta 1992, 1132:322-324.
163. Vaughan T.J., Pascall J.C., Brown K.D. Tissue distribution of mRNA for heparin-binding epidermal growth factor. Biochem. J. 1992, 287(Pt 3):681-684.
164. Velu T.J., Beguinot L., Vass W.C., Willingham M.C., Merlino G.T., Pastan I., Lowy D.R. Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science 1987, 238:1408-1410.
165. Vieira A.V., Lamaze C., Schmid S.L. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 1996, 274:2086-2089.
166. Viloria-Petit A., Crombet T., Jothy S., Hicklin D., Bohlen P., Schlaeppi J.M., Rak J., Kerbel R.S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies invivo: a role for altered tumor angiogenesis. Cancer Res. 2001, 61:5090-5101.
167. Wang S.C., Hung M.C. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2009, 15:6484-6489.
168. Wang Y., Minoshima S., Shimizu N. Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved fish technique. Jpn. J. Hum. Genet. 1993, 38:399-406.
169. Wang Y., Pennock S., Chen X., Wang Z. Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol. Cell. Biol. 2002, 22:7279-7290.
170. Watanabe T., Shintani A., Nakata M., Shing Y., Folkman J., Igarashi K., Sasada R. Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction. J. Biol. Chem. 1994, 269:9966-9973.
171. Wells A., Welsh J.B., Lazar C.S., Wiley H.S., Gill G.N., Rosenfeld M.G. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 1990, 247:962-964.
172. Wu S.L., Kim J., Bandle R.W., Liotta L., Petricoin E., Karger B.L. Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using extended range proteomic analysis (ERPA). Mol. Cell. Proteomics 2006, 5:1610-1627.
173. Xie Y., Hung M.C. Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. Biochem. Biophys. Res. Commun. 1994, 203:1589-1598.
174. Yamamoto H., Toyooka S., Mitsudomi T. Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 2009, 63:315-321.
175. Yamazaki H., Ohba Y., Tamaoki N., Shibuya M. A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn. J. Cancer Res. 1990, 81:773-779.
176. Yoder B.K., Richards W.G., Sommardahl C., Sweeney W.E., Michaud E.J., Wilkinson J.E., Avner E.D., Woychik R.P. Functional correction of renal defects in a mouse model for ARPKD through expression of the cloned wild-type Tg737 cDNA. Kidney Int. 1996, 50:1240-1248.
177. Yoshioka R., Shiraishi A., Kobayashi T., Morita S., Hayashi Y., Higashiyama S., Ohashi Y. Corneal epithelial wound healing impaired in keratinocyte-specific HB-EGF-deficient mice invivo and invitro. Invest. Ophthalmol. Visual Sci. 2010, 51:5630-5639.
178. Yu X., Sharma K.D., Takahashi T., Iwamoto R., Mekada E. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. Mol. Biol. Cell 2002, 13:2547-2557.
179. Yun C.H., Boggon T.J., Li Y., Woo M.S., Greulich H., Meyerson M., Eck M.J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007, 11:217-227.
180. Zhang Y., Wolf-Yadlin A., Ross P.L., Pappin D.J., Rush J., Lauffenburger D.A., White F.M. Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol. Cell. Proteomics 2005, 4:1240-1250.